All In Biotech

Drug Trial Radar · NCT05693129

Pediatric Patients Aged 1 to 6 Years With APDS

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

16

Actual

Start

Aug 30, 2023

Primary completion

Jul 9, 2028

Study completion Oct 28, 2028

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
Collaborators
CMIC Co, Ltd. Japan; Labcorp Central Laboratory; Fortrea; Aixial Group
First posted
Jan 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 1 to 6 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)

Conditions

  • APDS

Interventions

  • LeniolisibDrug

    The doses selected will range from 10 to 50 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 100 mg per day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days
  2. Part I & II: Change from baseline in clinical laboratory test resultsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
  3. Part I & II: Change from baseline in vital signsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
  4. Part I & II: Change from baseline in physical examination findingsTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
  5. Part I & II: Change from baseline in electrocardiograms (ECGs)Time frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year, plus 30 days
  6. Part I & II: Change from baseline in growth and physical developmentTime frame: From baseline to end of 12 weeks, & From baseline to through study completion, an average of 1 year
  7. Part I & II: Reduction in lymphadenopathy as measured by MRI or low-dose CTTime frame: Part I: Baseline and Day 85 Part II: at Day 252, through study completion, an average of 1 year
  8. Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B CellsTime frame: Part I: Baseline, Days 29, 57 and 85

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • National Institutes of Health

    Bethesda, Maryland

  • Rainbow Childrens Hospital

    Shaker Heights, Ohio

  • Texas Children's Hospital

    Houston, Texas

  • Kyoto University Hospital

    Kyoto, Japan

  • Institute of Science Tokyo Hospital

    Tokyo, Japan

  • Hospital Pediátrico de Coimbra da ULS Coimbra UNIDADE LOCAL DE SAÚDE DE COIMBRA

    Coimbra, Portugal

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.